Shares of Spectral Medical Inc. plunged nearly 85% on Monday as its phase III pivotal trial of Toraymyxin medical device for the treatment of patients with septic shock did not statistically achieve its primary end point of absolute reduction in mortality at 28 days.
from RTT - Biotech http://ift.tt/2dG5Kv3
via IFTTT
No comments:
Post a Comment